RNA Aptamer Therapeutics Pipeline — PatSnap Eureka
RNA Aptamer Therapeutics: Aptamer-Drug Conjugates & DNA Origami Delivery
From the single approved aptamer drug pegaptanib to multifunctional ApDCs, aptamer-siRNA chimeras, and DNA origami nanostructures—map the full nucleic acid therapeutic pipeline with AI-powered patent and literature intelligence from PatSnap Eureka.
Six Distinct Aptamer-Based Delivery Architectures
Retrieved patent and literature results identify six mechanistically distinct classes of aptamer-based therapeutic constructs, spanning from predominantly preclinical ApDCs to the earliest clinical signals in aptamer-siRNA chimera research.
Aptamer-Drug Conjugates (ApDCs)
Analogous to antibody-drug conjugates (ADCs), ApDCs use aptamers as targeting vectors conjugated to cytotoxic payloads. A 2021 review from Inha University classifies ApDC designs spanning chemotherapy payloads (including doxorubicin intercalation), photosensitizers, radionuclides, gene therapy cargoes, and vaccine constructs. ApDCs exhibit synergistic effects through dual mechanisms—receptor blockade and intracellular cargo action.
Stage: Predominantly preclinicalAptamer-siRNA Chimeras
Among the most mechanistically elaborated modalities in this dataset, aptamer-siRNA chimeras exploit cell-internalizing aptamers to co-deliver siRNA payloads into target cells, enabling dual-action: receptor inhibition and post-transcriptional gene silencing via RNAi. The University of Texas group pioneered PSMA aptamer-siRNA conjugates via a streptavidin bridge, demonstrating gene silencing comparable to lipid transfection reagents. Multiple independent groups—CNR Naples, City of Hope, Fundação Oswaldo Cruz—have validated this architecture.
Stage: Preclinical, early clinical signalDNA Origami & Nanostructure-Based Delivery
Structured DNA nanoarchitectures (polyhedra, pyramids, nanocages, tetrahedra) serve as delivery scaffolds and aptamer-display platforms. University of Hong Kong research found optimized nanostructure geometry improved aptamer sensitivity up to 6-fold over free aptamer. University of Massachusetts demonstrated AS1411 in DNA pyramids enhanced intracellular uptake and selectively inhibited cancer cell growth without transfection reagents, while substantially increasing nuclease resistance.
Stage: Early preclinicalAptamer-Nanoparticle Conjugates
Aptamers functionalized onto polymeric NPs, dendrimers, liposomes, gold nanoparticles, and inorganic NPs enable active targeting. A CNRS Toulouse review describes dendrimer-aptamer bioconjugates encapsulating epirubicin, camptothecin, Bcl-xL shRNA, and 5-fluorouracil for tumor-targeted delivery. Life sciences IP teams tracking this space will find broad published precedent across nanoparticle substrates.
Stage: Preclinical to early translationalMultimeric & Bispecific Aptamer Chimeras
Bispecific and multivalent aptamer constructs simultaneously engage two or more molecular targets. The Yeda Research and Development patent discloses multimeric aptamers incorporating monomers targeting ErbB receptors on nucleic acid nanostructures, enabling ligand clustering and avidity effects. A University at Albany paper describes composite RNA aptamers termed "aptabodies" with tetravalent architecture binding two copies each of distinct proteins, mimicking monoclonal antibody function.
Stage: Preclinical / conceptualIntracellular Vector-Expressed RNA Aptamers
Duke University Medical Center demonstrated an adenoviral vector approach using H1 RNA Polymerase III promoter to express pure RNA aptamers targeting intracellular proteins (NF-κB p50), achieving high-level inhibition of intracellular protein activity. This circumvents the limited intracellular penetration of exogenously delivered aptamers and represents a gene-therapy-adjacent modality for intracellular protein targeting.
Stage: Early preclinicalDisease Targets Driving Aptamer Therapeutic Development
Retrieved results converge on cancer as the dominant disease context for aptamer-based therapeutic development, with secondary applications in viral infection, inflammatory and autoimmune disease, neurodegeneration, and hematological disorders. The patent and literature landscape reveals a hierarchy of target maturity, from the clinically validated VEGF165/pegaptanib axis to emerging immunological targets like CD200R1.
Nucleolin (AS1411 target) emerges as the most architecturally elaborated aptamer target in this dataset. The G-quadruplex aptamer AS1411 linked to octahedral truncated DNA nanocages showed over 200-fold increased anti-cancer activity versus free aptamer, with selective internalization through a nucleolin-dependent mechanism (University of Rome Tor Vergata, 2021). Anti-nucleolin aptamers are also among those cited as undergoing clinical trials for cancer patients.
VEGF165 is the founding clinical target of RNA aptamer therapeutics—pegaptanib (Macugen) received FDA approval in December 2004 for neovascular age-related macular degeneration and remains the only approved aptamer drug identified in this dataset. Post-ExSELEX approaches using unnatural base pairs from Yokohama City University have yielded aptamers surpassing pegaptanib in thermal and nuclease stability.
PSMA (Prostate-Specific Membrane Antigen) is the target of the landmark 2006 University of Texas aptamer-siRNA conjugate demonstrating cell-type-selective RNAi delivery via streptavidin bridge—a proof-of-concept cited across multiple retrieved papers as foundational to the entire aptamer-siRNA chimera field. Life sciences IP teams should note the depth of prior art around PSMA-targeting aptamers.
CD200R1 (immune inhibitory receptor) is disclosed in a D5 Pharma European patent as a target for DNA aptamers with active legal status—covering inflammatory disease, spinal cord injury, transplantation, and autoimmune disorders including systemic lupus erythematosus, Parkinson's disease, and multiple sclerosis. This represents the most explicit patent-level disclosure of aptamer conjugation strategy in an immunological (non-oncology) context in this dataset, suggesting whitespace exists beyond oncology. According to the World Health Organization, autoimmune and inflammatory diseases represent a major unmet therapeutic need globally.
HIV-1 and HCV conserved RNA genomic elements are targeted by RNA aptamers described by IPBLN-CSIC (Granada, Spain), demonstrating antiviral activity—highlighting a nucleic acid target (rather than protein target) paradigm. NIH and global health agencies continue to prioritize antiviral nucleic acid therapeutic development.
Quantifying the Aptamer Therapeutic Landscape
Key data signals from retrieved patent and literature records, illustrating the activity improvement enabled by nanostructure display and the relative development stage of each therapeutic modality.
AS1411 Anti-Cancer Activity: Free Aptamer vs. DNA Nanocage
University of Rome Tor Vergata (2021) demonstrated >200-fold activity improvement when AS1411 is linked to octahedral truncated DNA nanocages versus free aptamer alone.
Aptamer Therapeutic Modalities by Development Stage
Six aptamer-based therapeutic modalities mapped by apparent development stage from retrieved patent and literature data. Aptamer-siRNA chimeras show the deepest mechanistic validation and earliest clinical signal.
Key Institutions and Commercial Entities in This Dataset
Retrieved results are overwhelmingly literature-driven (academic papers), with only 2 identifiable patent records—suggesting the aptamer-nucleic acid delivery field remains substantially in academic research mode, with commercial IP activity present but underrepresented.
| Institution / Company | Country | Key Contribution in Dataset | Type |
|---|---|---|---|
| University of Naples "Federico II" / CNR-IEOS | Italy | Aptamer-siRNA chimeras, TNBC aptamers, bispecific chimeras, precision oncology — highest-output group in dataset | Academic |
| City of Hope / Beckman Research Institute | USA | AptaBlocks RNA delivery design, RNAi nanoparticle delivery, aptamer therapeutics reviews | Academic |
| University of Hong Kong (Li Ka Shing) | HK | DNA aptamer display on DNA origami and polyhedra — distinct niche; 6-fold sensitivity improvement | Academic |
| University of Rome Tor Vergata | Italy | AS1411 on DNA nanocages: >200-fold anti-cancer activity improvement over free aptamer | Academic |
| D5 Pharma Inc. | EU (EP) | Active European patent: anti-CD200R1 DNA aptamers for inflammatory disease, autoimmune, neurodegeneration | Commercial / Patent |
| SomaLogic, Inc. | USA | Slow off-rate modified aptamers (SOMAmers) incorporating protein-like side chains at 5-position of uracil | Commercial |
| Yeda Research & Development Co. Ltd. | Israel (IL) | Multimeric ErbB-targeting aptamers on nucleic acid nanostructures (inactive patent) | Commercial / Patent (inactive) |
| Ribomic Inc. | Japan | Aptamer chemical properties and modifications for therapeutic applications; RNA plasticity and selectivity | Commercial |
Track Commercial IP Activity in Aptamer Therapeutics
PatSnap Eureka monitors patent filing velocity, assignee changes, and whitespace signals across 120+ patent jurisdictions.
What the Aptamer Pipeline Signals for R&D and IP Strategy
Key strategic conclusions derived from retrieved patent and literature records—for IP strategists, drug developers, and investors tracking the nucleic acid therapeutics space.
ApDCs: Most Clinically Proximate Beyond VEGF
Retrieved results identify cancer—particularly TNBC, leukemia, prostate, and pancreatic cancer—as the near-term indication space with the most mechanistically characterized aptamer-drug pairings. D5 Pharma holds the only active European patent in this dataset extending aptamer conjugation into immunology (CD200R1), suggesting whitespace exists beyond oncology for ApDC development.
Aptamer-siRNA Chimeras: Deepest Mechanistic Validation
The aptamer-siRNA chimera modality has the deepest mechanistic validation in this dataset across multiple independent research groups (CNR Naples, City of Hope, Fundação Oswaldo Cruz, University of Texas), yet no retrieved result describes this modality in clinical trials. Combined with the approval of three siRNA drugs (patisiran, givosiran, lumasiran), retrieved data suggest aptamer-mediated siRNA delivery is a plausible next convergence point for clinical development. Track this space via PatSnap analytics.
DNA Origami: Dramatic Efficacy Gains, No Clinical Translation Yet
DNA origami and nanostructure display of aptamers dramatically improve nuclease resistance and intracellular delivery efficiency—AS1411 on nanocage delivers >200-fold activity improvement over free aptamer. However, retrieved results contain no clinical translation for this approach. Investors and developers should monitor whether IND-enabling toxicology data emerges for nanostructured aptamer constructs.
Emerging Directions: AptaBlocks, Multimerization & In Vivo Production
City of Hope's AptaBlocks computational platform provides a generalizable design framework using double-stranded "sticky bridges" to conjugate aptamers with RNA therapeutic cargoes. University of Seoul describes chemical conjugation, structural self-assembly, enzymatic elongation (rolling circle transcription), and self-amplification as strategies for multimeric RNA therapeutics. Saint Petersburg State University highlights yeast (Saccharomyces cerevisiae) as a platform for in vivo synthesis of RNA nanoparticles including aptamers.
From Pegaptanib to the Next Wave of Approved Nucleic Acid Drugs
Retrieved results contain limited but notable clinical signals. Pegaptanib (Macugen) — an anti-VEGF165 RNA aptamer (pegylated, 2′-modified) — received FDA approval in December 2004 for neovascular age-related macular degeneration, and remains the only explicitly approved aptamer drug identified in retrieved results.
A UC Davis paper explicitly lists three FDA-approved siRNA drugs—patisiran, givosiran, and lumasiran—alongside pegaptanib, signaling that aptamer-conjugated siRNA delivery systems may eventually reach the same regulatory pathway. The FDA's approval of Onpattro (patisiran-LNP) in 2018 opened a regulatory pathway for nanomedicine-based RNA therapies, with a wide variety of NP formulations now in clinical trials for microRNA, siRNA, and mRNA delivery (University of Southern California, 2022).
A National Cancer Center Korea paper retrieved in this dataset states that aptamers targeting nucleolin and CXCL12 are undergoing clinical trials for cancer patients—the most explicit reference to ongoing clinical trial activity in the aptamer space within this dataset.
Retrieved results contain no explicit clinical trial data for ApDCs or DNA origami-based delivery systems, consistent with the predominantly early preclinical state of these specific modalities. PatSnap customers in biopharma use Eureka to monitor IND-enabling data emergence and regulatory milestone signals across nucleic acid therapeutic programs. The European Medicines Agency and global health regulators are increasingly active in establishing frameworks for nucleic acid therapeutics. For deeper API-level integration of clinical and patent data, see PatSnap Open API.
The aptamer-siRNA triple combination approach—aptamer + siRNA + chemotherapy in nanoparticle formats (Fundação Oswaldo Cruz, 2019)—represents a convergent design exploiting aptamer binding specificity, siRNA gene silencing, and cytotoxic chemotherapy synergistically, and is identified as an active direction for next-generation ApDC design.
RNA Aptamer Therapeutics — Key Questions Answered
Pegaptanib (Macugen) is the only explicitly approved aptamer drug identified in retrieved results. It is an anti-VEGF165 RNA aptamer (pegylated, 2′-modified) approved by the FDA in December 2004 for neovascular age-related macular degeneration.
ApDCs are an emerging class of targeted therapeutics analogous to antibody-drug conjugates (ADCs), where aptamers serve as targeting vectors conjugated to cytotoxic payloads. ApDCs exhibit synergistic therapeutic effects through dual mechanisms—receptor blockade by the aptamer and intracellular cargo action. Payload types span chemotherapy (including doxorubicin intercalation), photosensitizers for photodynamic therapy, radionuclides, gene therapy cargoes, and vaccine constructs.
A study from the University of Rome Tor Vergata demonstrated that AS1411 linked to octahedral truncated DNA nanocages showed over 200-fold increased anti-cancer activity compared to free aptamer, with selective internalization in cancer cells through a nucleolin-dependent mechanism.
A National Cancer Center Korea paper retrieved in this dataset states that aptamers targeting nucleolin and CXCL12 are undergoing clinical trials for cancer patients. This is the most explicit reference to ongoing clinical trial activity in the aptamer space within this dataset.
Aptamer-siRNA chimeras exploit cell-internalizing aptamers to co-deliver siRNA payloads into target cells, enabling dual-action: receptor inhibition by the aptamer moiety and post-transcriptional gene silencing by siRNA via RNAi. The University of Texas group pioneered PSMA aptamer-siRNA conjugates via a streptavidin bridge, demonstrating siRNA-mediated gene silencing comparable to lipid transfection reagents.
City of Hope results describe the AptaBlocks computational method using double-stranded "sticky bridges" to conjugate cell-internalizing aptamers with RNA therapeutic cargoes, providing a generalizable design framework for aptamer-cargo constructs.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About Aptamer TherapeuticsAccelerate Your Nucleic Acid Therapeutic Research with AI-Powered Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from aptamer target identification to ApDC IP landscaping and clinical signal monitoring.
References
- AS1411 Aptamer Linked to DNA Nanostructures Diverts Its Traffic Inside Cancer Cells and Improves Its Therapeutic Efficacy — University of Rome Tor Vergata (2021)
- Post-ExSELEX stabilization of an unnatural-base DNA aptamer targeting VEGF165 toward pharmaceutical applications — Yokohama City University (2016)
- Aptamer mediated siRNA delivery — University of Texas at Austin (2006)
- Optimization of Short RNA Aptamers for TNBC Cell Targeting — CNR-IEOS, Naples (2022)
- H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity — Duke University Medical Center (2006)
- Two Interconvertible Folds Modulate the Activity of a DNA Aptamer Against Transferrin Receptor — Istituto Italiano di Tecnologia, Pisa (2014)
- Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy — Inha University College of Medicine (2021)
- DNA Aptamers for the Functionalisation of DNA Origami Nanostructures — University of Hong Kong (2018)
- Aptamer-Targeted DNA Nanostructures for Therapeutic Delivery — University of Massachusetts, Amherst (2014)
- Dendrimer– and polymeric nanoparticle–aptamer bioconjugates as nonviral delivery systems — CNRS Toulouse (2020)
- Coupling Aptamers to Short Interfering RNAs as Therapeutics — CNR-IEOS Naples (2011)
- Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives — University of Naples "Federico II" (2018)
- Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents — SomaLogic, Inc. (2014)
- Therapeutic aptamers: developmental potential as anticancer drugs — National Cancer Center, Korea (2015)
- Two Examples of RNA Aptamers with Antiviral Activity. Are Aptamers the Wished Antiviral Drugs? — IPBLN-CSIC Granada (2020)
- Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination — UC Davis (2022)
- Clinical progress of nanomedicine-based RNA therapies — University of Southern California (2022)
- Multimeric RNAs for efficient RNA-based therapeutics and vaccines — University of Seoul (2022)
- Pharmaceutical applications of framework nucleic acids — Sun Yat-sen University (2022)
- World Health Organization — Global Disease Burden and Unmet Therapeutic Need
- National Institutes of Health — Nucleic Acid Therapeutics Research
- U.S. Food and Drug Administration — RNA Therapeutic Drug Approvals
- European Medicines Agency — Nucleic Acid Therapeutic Regulatory Frameworks
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.